Steady Concentration Peritoneal Dialysis – SCPD

Learn more

Triomed is rethinking Peritoneal Dialysis with SCPD

Worldwide there are over 3 500 000 dialysis patients. Only approximately 10% of these patients are treated with Peritoneal Dialysis even though Peritoneal Dialysis is generally considered the treatment of choice by both patients and healthcare providers

Triomed is developing innovative systems to address the key limitations of Peritoneal Dialysis. Systems to ensure that Peritoneal Dialysis becomes the preferred dialysis alternative for End-Stage Kidney Disease patients, and help patients stay on Peritoneal Dialysis longer

By continually recirculating and regenerating dialysate fluid, Triomed SCPD maintains a constant osmotic gradient over the patient’s peritoneal membrane, something traditional Peritoneal Dialysis does not do.

Award winning clinical studies have shown that Triomed SCPD leads to a significant increase in the removal of water and salt from Peritoneal Dialysis patients and a significant improvement in glucose efficiency

Read more

Addressing the challenge of volume management in Peritoneal Dialysis patients

The inability to maintain adequate volume status in Peritoneal Dialysis patients is strongly linked to  technique failure, cardiac dysfunction, inflammation and is a strong predictor of poor patient outcomes like hospitalization and mortality

Triomed SCPD aims to reduce technique failure and comorbidities by improving volume management

  • Enabling adequate fluid removal even in the absence of residual renal function
  • Enabling sodium removal to match dietary intake
Read more

Addressing the challenge of metabolic syndrome and membrane preservation while improving the quality of life of dialysis patients

Long-term exposure to hypertonic glucose solutions negatively impacts the transport characteristics of the peritoneal membrane and is associated with metabolic syndrome

Triomed SCPD aims to improve glucose efficiency and diminish the need for hypertonic glucose solutions

  • Reduced risk of metabolic complications
  • Reduced risk of membrane burnout

Peritoneal Dialysis requires a large, constant supply and storage of sterile fluids and most often a bulky machine, both of which take space in the patient’s home

Triomed SCPD aims to improve the quality of life for dialysis patients

  • Increasing treatment flexibility by tailoring the treatment to patient needs
  • Increasing patient independence and mobility – less fluids, smaller cyclers
Read more

A team with over 300 years of dialysis experience

Board of Directors

Mats Wahlström

Mats Wahlström has been the Chairman of the Board since 2016. Mats has more than 35 years of international experience in health care from positions such as CFO and Executive Vice President of the Gambro Group, CEO of Gambro Healthcare Inc, Co-CEO of Fresenius Medical Care North America, CEO of Fresenius Medical Services, and as a member of the Management Board for Fresenius Medical Care AG & Co. KGaA. Mats is active in a number of corporate boards.

Anders Helmner

Member of the Board of Directors since 2012 and a co-founder of Triomed. Anders Helmner has been involved in the development, production and distribution of medium-haul components for commercial aircraft. He has also built up the global distribution of components for long-haul commercial aircraft.

Ulf Öjerklint

Member of the Board of Directors since 2012. Ulf is a lawyer and senior partner at WSA law firm. He has extensive commercial law and corporate transaction experience. Ulf is active in a number of corporate boards.

Ugo Grondelli

Ugo has been a member of the Board of Directors since 2012.  Ugo Grondelli has a Masters of Science in Business and Economics and an MBA from UCLA (University of California).  Ugo owns Spindial Europé S. A., a company within the dialysis and intensive care market. Previous experience includes Executive Vice President of the Gambro group, Chairman of the Board of Hospal AG, Switzerland, Vice President of Jostra AG, Germany, and Board member of Q-Med AB. Ugo is active in a number of corporate boards.

Juan Bosch

Member of the Board of Directors since 2016. Dr Bosch is a Nephrologist with extensive experience in clinical medicine, nephrology and research in artificial organs. Juan was the Chief Medical Officer of the Gambro group and Professor with Tenure at George Washington University.

Lars Persson

Member of the Board of Directors since 2012.  Lars has experience from leading positions within MedTech Venture Capital including Almi and Industrifonden. Lars is active on the Board of a number of medical technology companies.

Anders Wallenås

Member of the Board of Directors since 2016 and a co-founder of Triomed. Anders Wallenås has a Master of Science in Mechanical Engineering. He has more than 30 years of experience managing industrial development projects across a range of industries.

Lars Wramner

Member of the Board since 2020 and a co-founder of Triomed. Dr. Wramner is a transplant surgeon and was previously employed as a Director of Education within the Swedish Armed forces.

Management

Patrick Greatrex

Patrick Greatrex has been the CEO of Triomed since 2016.  Prior to joining Triomed Patrick had a number of CEO and senior management roles in life science companies including CEO of Vivoline Medical AB and Vice President of Business Development at Gambro AB. Patrick has been awarded Bachelor Degrees in Law and Arts from the University of Queensland and an MBA from Lund University.

Amanda Monthan

Amanda Monthán has been employed at Triomed since 2019 and is Triomed’s QA/RA Manager. Amanda has worked in the Medical device industry since 2004, and has experience from specialist roles within Quality Assurance and R&D organizations at Baxter International Inc, Gambro AB and BD Infusion Therapy systems AB. She holds a Master of Science degree from Lund University.

Charlotte de Leon

Charlotte de Leon has been with Triomed since 2013. She is currently employed as the Clinical and Project Manager. Charlotte has been awarded a PhD in medicine and has a background in research, including post-doctoral studies at Harvard Medical School.

Hans Bengtsson

Hans Bengtsson joined Triomed AB in 2012. Hans leads the development of Triomed’s active devices. Hans has an MSc in Mechanical Engineering and more than 20 years’ experience of leading research and developments projects.

Nina Meinander

Nina Meinander joined Triomed AB in 2012. Nina leads the development of Triomed’s disposable products. Nina Meinander has 13 years’ experience from pharmaceutical research and development, and has an MSc in Chemical Engineering and a PhD in Applied Microbiology/Biotechnology.